The eyes in diabetes and diabetes through the eyes

被引:9
作者
Harman-Boehm, Ilana [1 ,2 ]
Sosna, Tomas [3 ]
Lund-Andersen, Henrik [4 ,5 ]
Poita, Massimo [6 ]
机构
[1] Soroka Univ, Med Ctr, Dept Internal Med C, Beer Sheva, Israel
[2] Soroka Univ, Med Ctr, Diabet Unit, Beer Sheva, Israel
[3] IKEM, Cent Diabetol, Prague, Czech Republic
[4] Univ Dept Herlev Hosp, Copenhagen, Denmark
[5] Steno Diabet Ctr, Copenhagen, Denmark
[6] Univ Turin, Turin, Italy
关键词
diabetic retinopathy; protein kinase C; renin-angiotensin system; microvascular complications; AGE; polyols;
D O I
10.1016/j.diabres.2007.09.023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetic retinopathy (DR) is the most common of the microvascular complications of diabetes. Left unchecked and untreated, it could progresses from a non-proliferative phase to a proliferative, sight-threatening phase. Macular edema which also threatens sight can appear at any stage. The pathophysiological mechanisms underlying its appearance and progression include the accumulation of plyols, advanced glycation endproducts (AGE) reactive oxygen species, release of local growth factors and activation of protein kinase C, all of which lead to structural and functional changes in the retina which can progress to threaten sight. Tight glucose and blood pressure control can prevent the appearance and progression of retinopathy. Novel PKC inhibitors, inhibitors of growth factors, blockers of the renin-angiotensin system (RAS) as well as statins can slow the progression of DR and protect sight. (c) 2007 Published by Elsevier Ireland Ltd.
引用
收藏
页码:S51 / S58
页数:8
相关论文
共 49 条
[1]   Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study [J].
Adler, AI ;
Stratton, IM ;
Neil, HAW ;
Yudkin, JS ;
Matthews, DR ;
Cull, CA ;
Wright, AD ;
Turner, RC ;
Holman, RR .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7258) :412-419
[2]  
[Anonymous], 1996, DIABETES, V45, P1289
[3]  
Chakrabarti S, 2000, DIABETES-METAB RES, V16, P393, DOI 10.1002/1520-7560(0000)9999:9999<::AID-DMRR157>3.0.CO
[4]  
2-G
[5]   Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes [J].
Chaturvedi, N ;
Sjolie, AK ;
Stephenson, JM ;
Abrahamian, H ;
Keipes, M ;
Castellarin, A ;
Rogulja-Pepeonik, Z ;
Fuller, JH .
LANCET, 1998, 351 (9095) :28-31
[6]   Obesity and eye diseases [J].
Cheung, Ning ;
Wong, Tien Y. .
SURVEY OF OPHTHALMOLOGY, 2007, 52 (02) :180-195
[7]   Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy - Early treatment diabetic retinopathy study (ETDRS) report 22 [J].
Chew, EY ;
Klein, ML ;
Ferris, FL ;
Remaley, NA ;
Murphy, RP ;
Chantry, K ;
Hoogwerf, BJ ;
Miller, D .
ARCHIVES OF OPHTHALMOLOGY, 1996, 114 (09) :1079-1084
[8]   The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy? [J].
Chowdhury, T ;
Hopkins, D ;
Dodson, PM ;
Vafidis, GC .
EYE, 2002, 16 (06) :689-693
[9]   Retinal blood flow in diabetes [J].
Clermont, Allen C. ;
Bursell, Sven-Erik .
MICROCIRCULATION, 2007, 14 (01) :49-61
[10]  
Davis MD, 1998, INVEST OPHTH VIS SCI, V39, P233